Common Stock, $0.02 par value per share
- Symbol
- DSS
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 9.01 · 8-K
DSS, Inc.
DSSNYSE_AMERICANEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement with Alset Inc. On September 15, 2026, DSS, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Alset Inc., a Texas corporation (“Alset”), pursuant to which Alset has loaned the Company $500,000, in exchange for a convertible promissory note (the “Note”) and warrants to purchase 8,000…
Company context
DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our,” or the “Company”) is a multi-segment operating company focused on packaging, biotechnology, financial services, and investment platform businesses. The Company operates through four principal business segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Through these segments, the Company seeks to develop and operate businesses across industries where management believes opportunities exist to create long-term shareholder value through operational growth, strategic partnerships, and the development or acquisition of complementary business platforms.
Current securities
Registered securities in this filing
DSS, INC. · 8-K · Filed 2026-09-21
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item
1.01 Entry into a Material Definitive Agreement.
Securities
Purchase Agreement with Alset Inc.
On
September 15, 2026, DSS, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Alset
Inc., a Texas corporation (“Alset”), pursuant to which Alset has loaned the Company $500,000, in exchange for a convertible
promissory note (the “Note”) and warrants to purchase 8,000,000 shares of the Company’s common stock (the “Warrants”).
The Note, SPA, and Warrants are collectively referred to herein as the “Transaction Documents.”
The
Note is payable upon demand. The Note bears simple interest at 3% per annum. Alset may convert any outstanding principal and interest
into shares of the Company’s common stock at $0.50 per share upon notice prior to maturity of the Note, which is five (5) years
from the date thereof.
The
Warrants are to purchase up to 8,000,000 shares of the Company’s common stock at an exercise price of $0.55 per share. The Warrants
expire on their fifth anniversary.
The
Transaction Documents will require the approval of the Company’s stockholders prior to the conversion of the Note or exercise of
the Warrants.
Alset
holds a significant equity interest in the Company directly and through its subsidiaries. The Company and Alset are related parties under
the common control of the Company’s Chairman, Chan Heng Fai, who is also the Chairman and Chief Executive Officer of Alset. Chan
Tung Moe, a director and Co-Chief Executive Officer of Alset, is also a director of the Company. Lim Sheng Hon Danny, a director and
officer of Alset, is also a director of the Company. Three of the Company’s independent directors, Joanne Wong Hiu Pan, Wong Shui
Yeung, and William Wu, are also directors of Alset.
The
Transaction Documents were approved by the Company’s Board of Directors and Audit Committee.
The
foregoing is a summary only and does not purport to be complete. It is qualified in its entirety by reference to the Transaction Documents,
copies of which are filed as Exhibits 10.1, 10.2, and 10.3 hereto and incorporated by reference herein.